IDEAYA Q4 profit slightly beats estimates

IDEAYA Biosciences

17/02/2026 11:08

Overview

Precision medicine oncology firm's Q4 EPS and net income slightly beat analyst expectations

Q4 collaboration revenue rose compared to the same period last year

Company anticipates topline results from Phase 2/3 trial in metastatic uveal melanoma by March end

Outlook

IDEAYA expects topline results from darovasertib trial by end of March 2026

Company anticipates three Phase 3 trials for darovasertib by H1 2026

IDEAYA plans IDE849 registrational study in SCLC by end of 2026

Result Drivers

CLINICAL TRIAL PROGRESS - IDEAYA completed full enrollment in its Phase 2/3 trial for metastatic uveal melanoma, with topline results expected by March end

PIPELINE EXPANSION - Co initiated IND filings for IDE034 and IDE574, expanding its clinical pipeline

FINANCIAL POSITION - IDEAYA reported $1.05 bln in cash and equivalents, expected to fund operations into 2030

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$10.88 mln
Q4 EPS
Beat
-$0.94
-$0.97 (17 Analysts)
Q4 Net Income
Slight Beat*
-$83.27 mln
-$83.37 mln (15 Analysts)
Q4 Profit From Operations
Beat
-$94.57 mln
-$96.32 mln (16 Analysts)
Q4 Operating Expenses
$105.45 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $48.00, about 58.6% above its February 13 closing price of $30.27

Press Release: ID:nPn6yX2DKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)